Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
f8il10
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
F8IL10 (also known as Dekavil) is a fully human recombinant fusion protein that combines the antibody fragment F8 with the anti-inflammatory cytokine interleukin-10 (IL-10). The F8 antibody targets the extra-domain A of fibronectin (ED-A), which is abundantly expressed in inflamed tissues such as those found in rheumatoid arthritis. By delivering IL-10 directly to sites of inflammation via this targeting mechanism, F8IL10 aims to maximize local immunosuppressive effects while minimizing systemic exposure. The drug has been developed primarily for rheumatoid arthritis and other inflammatory diseases. It has been evaluated in combination with methotrexate and as monotherapy via intravenous and intra-articular administration[3][4][5].
- Brand names
- Dekavil
- Other names
- F8 IL10F-8 IL10F 8 IL10F8-IL10F-8-IL10F 8-IL10PF 06687234PF06687234PF-06687234
02
Targets
EDA (Extra domain A-fibronectin)IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on f8il10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on f8il10.